World Journal of
Pharmaceutical and Life Sciences

IN-VITRO EVALUATION OF CELL VIABILITY STUDIES OF SQUAMOUS CELL CARCINOMA USING SIMILAR MOLECULE – SONIDEGIB

Arshiya Tarannum*, Dr. Syed Ahmed Hussain, Umaima Batool Osmani, Raheem Unnisa Shaik, Maimuna Fatima, Faheem Unnisa and Nazneen

ABSTRACT

Aim: This study aimed to evaluate the efficacy of Sonidegib, a PD-1 inhibitor, in inhibiting cell proliferation in kidney cancer cell lines using various cell viability assays. Objective: The objective was to compare Sonidegib's anticancer activity with the widely used chemotherapy drug Cisplatin and analyze its effectiveness at different concentrations. Research: The research employed five distinct assays—MTT, CellTiter-Glo Luminescent, Alamar Blue, SRB, and LDH Cytotoxicity—to measure the effects of Sonidegib on cell viability. Kidney cancer cell lines were treated with Sonidegib at concentrations of 1 μM, 5 μM, and 10 μM for 24–72 hours. Each assay provided unique insights into cell viability, metabolic activity, and cytotoxicity. The data indicated a concentration-dependent decrease in cell viability across all assays. Conclusion: Sonidegib demonstrated significant cytotoxic effects against kidney cancer cells, comparable to Cisplatin at higher concentrations. These findings suggest Sonidegib as a potential alternative treatment for renal cancer.

[Full Text Article]   [Download Certificate]